While injectable drugs, including some innovator anti–tumor necrosis factor inhibitors and their biosimilars, have revolutionized the treatment of rheumatic diseases like rheumatoid arthritis (RA), hand disability can limit the ability of patients with RA to use syringes to administer medication. Prefilled, disposable auto-injectors may help to alleviate this issue and have demonstrated acceptability studies, but questions have remained about whether patients with reduced manual dexterity may still experience needle displacement when using these devices.
While injectable drugs, including some innovator anti—tumor necrosis factor inhibitors and their biosimilars, have revolutionized the treatment of rheumatic diseases like rheumatoid arthritis (RA), hand disability can limit the ability of patients with RA to use syringes to administer medication. Prefilled, disposable auto-injectors may help to alleviate this issue and have demonstrated acceptability studies, but questions have remained about whether patients with reduced manual dexterity may still experience needle displacement when using these devices.
A study newly published in Patient Preference and Adherence reports on researchers’ efforts to track the motions of 29 patients with RA who had varying degrees of disability and 9 volunteers without RA as they administered injections to measure the performance of simulated self-injection.
Each individual was asked to perform 2 simulated subcutaneous self-injections using a foam pad attached to a common injection site (1 on the thigh and 1 on the abdomen). Motion was tracked with an electromagnetic motion capture system to track the positions and orientations of the injector and pad. The individuals were given instructions on how to administer the injection, and motion data were streamed and exported for analysis.
In assessing needle displacement in injections, the authors say that, while there were differences between the RA group and the non-RA group in terms of needle displacement, these differences did not reach statistical significance. However, in both groups, injections performed on the abdomen had larger needle displacement than the injections performed on thigh (P = .025). Approximately 60% of patients reached the 90th percentile of their personal displacement within the first 15 seconds of the injection, with little variation over longer injections.
The mean percentage of correctly executed steps for administering the injection was 96.05% for the first injection and 98.02% for the second injection for both groups. In the RA group, the mean percentages were 95.69% and 98.71%.
The authors say that the percentage of patients who successfully handled the auto-injector suggests that the system is easy to use, even for patients with limited dexterity due to RA.
Reference
Xiao X, Li W, Clawson C, Karvani D, Sondag P, Hahn JK. Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system. Patient Prefer Adherence. 2018; 12:515-526. doi: 10.2147/PPA.S160394.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
Comparable Disease Activity, Drug Persistence in Patients With JIA Who Switch to Biosimilars
September 12th 2024Switching children with juvenile idiopathic arthritis (JIA) from anti–tumor necrosis factor originators to biosimilars showed similar disease activity and drug persistence, with good tolerability, supporting the safety and effectiveness of non-medical switching.